“Superbug” is shorthand for multi-drug resistant bacteria. Infections with superbugs are the most difficult to treat, because these bacteria have evolved ways of evading multiple — and sometimes all! — of our available antibiotics. This multi-drug resistance can arise in the bacteria that are causing disease, meaning doctors have to find new ways to treat the infection, but also in the bacteria that harmlessly live in our gastrointestinal tract. Critically, if these gut bacteria become superbugs, they can spread resistance throughout a hospital setting via fecal-oral contamination. On this episode of the Bio Eats World Journal Club, we discuss a new strategy for protecting those harmless bacteria from antibiotics while still treating the infection. Host Lauren Richardson is joined by Professor Andrew Read of Penn State University to discuss his team’s recent article “An adjunctive therapy administered with an antibiotic prevents enrichment of antibiotic-resistant clones of a colonizing opportunistic pathogen“, published in eLife. In it, they demonstrate that they can prevent resistance evolution in the gut by repurposing an old, FDA-approved drug. The conversation covers the scope of the antibiotic resistance problem, the insights that lead to the discovery of this adjuvant therapy, and the fundamentally novel nature of anti-evolution drugs.
Andrew F. Read
- Quantifying Disease Risk Using Genomics: the New Paradigm Peter Donnelly, Vineeta Agarwala, and Lauren Richardson
- Bio Eats World: Engineering an Epigenome Editor Jonathan Weissman, Vijay Pande, and Lauren Richardson
- Bio Eats World: Evolving Embodied Intelligence Li Fei-Fei, Surya Ganguli, Vijay Pande, and Lauren Richardson
- Bio Eats World: The Problem with Urgent Care Vineeta Agarwala, Justin Larkin, and Lauren Richardson
- Bio Eats World: Viral Genomes from A to Z Judy Savitskaya and Lauren Richardson
- Quantifying Disease Risk Using Genomics: the New Paradigm Peter Donnelly, Vineeta Agarwala, and Lauren Richardson
- Bio Eats World: Engineering an Epigenome Editor Jonathan Weissman, Vijay Pande, and Lauren Richardson
- Bio Eats World: Evolving Embodied Intelligence Li Fei-Fei, Surya Ganguli, Vijay Pande, and Lauren Richardson
- Bio Eats World: The Problem with Urgent Care Vineeta Agarwala, Justin Larkin, and Lauren Richardson
- Bio Eats World: Viral Genomes from A to Z Judy Savitskaya and Lauren Richardson
Insights, analysis, and additional reading on bio and health, and how both are shaping our future.
Learn MoreStreamlining the Patient Referrals Chain with Trey Holterman
From Chaos to Clarity in Data with Malinka Walaliyadde
Fueling Innovation with Data with Arif Nathoo
Want More Bio+Health?
Insights, analysis, and additional reading on bio and health, and how both are shaping our future.
Want More Bio+Health?
Insights, analysis, and additional reading on bio and health, and how both are shaping our future.
Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.
The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.
Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.
There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.
With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.
For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.